Investigating adenylate kinase 1 (Ak1) as a glial‐based therapeutic target in a mouse α‐synucleinopathy model
Our preliminary results indicate that Ak1<sup>-/-</sup> mice have fewer reactive astrocytes and less total and phosphorylated α-synuclein than their wild-type littermates at 1 and 3 months post-injection of AAV2-α-synuclein. These results support further investigation of Ak1 as a potential glial-based therapeutic target in α-synucleinopathies.
Authors
- Abby L. Olsen (ORCID: https://orcid.org/0000-0002-7680-1758)
- Maggie J. Sodders (ORCID: https://orcid.org/0000-0001-6009-1264)
- Archana Marathi
- Namrata Kumari (ORCID: https://orcid.org/0000-0002-3239-7220)
Institutions
- University of Pittsburgh (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70855_103171
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00